Johnson & Johnson Comprehensive Income 2010-2024 | JNJ
Johnson & Johnson comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Johnson & Johnson comprehensive income for the quarter ending September 30, 2024 was $-12.522B, a 42.62% increase year-over-year.
- Johnson & Johnson comprehensive income for 2023 was $-12.527B, a 3.39% decline from 2022.
- Johnson & Johnson comprehensive income for 2022 was $-12.967B, a 0.7% decline from 2021.
- Johnson & Johnson comprehensive income for 2021 was $-13.058B, a 14.33% decline from 2020.
Johnson & Johnson Annual Comprehensive Income
(Millions of US $) |
| 2023 |
$-12,527 |
| 2022 |
$-12,967 |
| 2021 |
$-13,058 |
| 2020 |
$-15,242 |
| 2019 |
$-15,891 |
| 2018 |
$-15,222 |
| 2017 |
$-13,199 |
| 2016 |
$-14,901 |
| 2015 |
$-13,165 |
| 2014 |
$-10,722 |
| 2013 |
$-2,860 |
| 2012 |
$-5,810 |
| 2011 |
$-5,632 |
| 2010 |
$-3,531 |
| 2009 |
$-3,058 |
Johnson & Johnson Quarterly Comprehensive Income
(Millions of US $) |
| 2024-09-30 |
$-12,522 |
| 2024-06-30 |
$-11,253 |
| 2024-03-31 |
$-10,768 |
| 2023-12-31 |
$-12,527 |
| 2023-09-30 |
$-8,780 |
| 2023-06-30 |
$-13,135 |
| 2023-03-31 |
$-12,626 |
| 2022-12-31 |
$-12,967 |
| 2022-09-30 |
$-15,292 |
| 2022-06-30 |
$-13,843 |
| 2022-03-31 |
$-13,757 |
| 2021-12-31 |
$-13,058 |
| 2021-09-30 |
$-15,415 |
| 2021-06-30 |
$-15,100 |
| 2021-03-31 |
$-15,328 |
| 2020-12-31 |
$-15,242 |
| 2020-09-30 |
$-14,938 |
| 2020-06-30 |
$-15,533 |
| 2020-03-31 |
$-16,243 |
| 2019-12-31 |
$-15,891 |
| 2019-09-30 |
$-15,533 |
| 2019-06-30 |
$-14,969 |
| 2019-03-31 |
$-15,517 |
| 2018-12-31 |
$-15,222 |
| 2018-09-30 |
$-14,647 |
| 2018-06-30 |
$-14,777 |
| 2018-03-31 |
$-12,608 |
| 2017-12-31 |
$-13,199 |
| 2017-09-30 |
$-12,747 |
| 2017-06-30 |
$-13,234 |
| 2017-03-31 |
$-14,522 |
| 2016-12-31 |
$-14,901 |
| 2016-09-30 |
$-12,715 |
| 2016-06-30 |
$-12,707 |
| 2016-03-31 |
$-12,391 |
| 2015-12-31 |
$-13,165 |
| 2015-09-30 |
$-12,861 |
| 2015-06-30 |
$-12,054 |
| 2015-03-31 |
$-13,300 |
| 2014-12-31 |
$-10,722 |
| 2014-09-30 |
$-5,382 |
| 2014-06-30 |
$-3,007 |
| 2014-03-31 |
$-2,645 |
| 2013-12-31 |
$-2,860 |
| 2013-09-30 |
$-5,346 |
| 2013-06-30 |
$-6,810 |
| 2013-03-31 |
$-6,689 |
| 2012-12-31 |
$-5,810 |
| 2012-09-30 |
$-4,925 |
| 2012-06-30 |
$-6,204 |
| 2012-03-31 |
$-4,540 |
| 2011-12-31 |
$-5,632 |
| 2011-09-30 |
$-3,068 |
| 2011-06-30 |
$-1,192 |
| 2011-03-31 |
$-2,020 |
| 2010-12-31 |
$-3,531 |
| 2010-09-30 |
$-2,924 |
| 2010-06-30 |
$-5,705 |
| 2010-03-31 |
$-3,837 |
| 2009-12-31 |
$-3,058 |
| 2009-09-30 |
$-2,661 |
| 2009-06-30 |
$-4,481 |
| 2009-03-31 |
$-5,169 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$374.313B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
